I'm not sure inhalable is a feature. Insulin pumps/pods micro-dose fast acting insulin throughout the day to cover your basal dose, you can't do that with fast-acting insulin via inhaler. You can't close loop your inhaler with a CGM to adjust your basal based on your current BG and automatically control for overnight highs/lows. You can't dose your kid from across the room from your smartphone.
Also there seems to be a a notable incidence of lung cancer which raises a bit of a yellow flag there...
I think alternative delivery mechanisms to injection are a feature. Ask any diabetic if they would like less needles in their bodies. There is work and patents on adjustable dose inhaler systems, but its never going to be a basal insulin that is being delivered. It's prandial.
The lung cancer concerns come from the only previous inhaled insulin Exhubra, which was literally vaporized insulin solution and offered no pharmacological benefit over injected insulin. The two instances of lung cancer in the 12(?) years of Afrezza testing occurred with patients who were smokers.
I'm not saying that Afrezza is the greatest invention ever, but it is a substantial step up from other mealtime insulins in my opinion.
Also there seems to be a a notable incidence of lung cancer which raises a bit of a yellow flag there...